Table 2.
Mean ± standard deviation changes in smoking and drug-induced movement disorders during 4-week stabilization on varenicline
| Measure | Study visit | ||||
|---|---|---|---|---|---|
|
| |||||
| Screen Week 0 | Baselinea Week 2 | Week 3 | Week 6 | Change in mean scores (Week 6−Week 2) | |
| TLFBb | 10.3 ± 2.9 | 14.7 ± 4.1 | 12.7 ± 5.2 | 8.3 ± 2.4 | −6.3 ± 4.5 |
| COc | 19.3 ± 5.8 | 17.0 ± 11.4 | 8.3 ± 1.7 | 11.0 ± 4.2 | −6.0 ± 9.4 |
| AIMSd | 8.7 ± 5.2 | 7.7 ± 3.1 | 9.0 ± 5.7 | 8.7 ± 4.1 | ＋1.0 ± 2.2 |
| SASe | 3.7 ± 4.5 | 3.0 ± 4.2 | -g | 2.3 ± 2.6 | −0.7 ± 1.7 |
| BASf | 3.7 ± 2.6 | 3.3 ± 2.4 | -g | 3.7 ± 2.6 | ＋0.3 ± 0.5 |
aVarenicline titration initiated at baseline, bTimeline-Follow Back mean daily cigarette consumption, cCarbon monoxide exhaled in parts per million (ppm), dAbnormal Involuntary Movement Scale, eSimpson Angus Scale, fBarnes Akathisia Scale, gSAS and BAS were not performed at week 3.